Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 20/20 | 1.00 |
| ▸ | PDE3B | Q13370 | 3/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 3/20 | 1.00 |
| ▸ | PDE1A | P54750 | 2/20 | 0.84 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.84 |
| ▸ | PDE1C | Q14123 | 2/20 | 0.84 |
| ▸ | PDE2A | O00408 | 1/20 | 0.84 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.84 |
| ▸ | ABCC5 | O15440 | 1/20 | 0.84 |
| ▸ | PDE6D | O43924 | 1/20 | 0.84 |
| ▸ | PDE8A | O60658 | 1/20 | 0.84 |
| ▸ | PDE9A | O76083 | 1/20 | 0.84 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.84 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.84 |
| ▸ | HTR1A | P08908 | 1/20 | 0.84 |
| ▸ | PDE6A | P16499 | 1/20 | 0.84 |
| ▸ | PDE6G | P18545 | 1/20 | 0.84 |
| ▸ | PDE4A | P27815 | 1/20 | 0.84 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.84 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lodenafil SCHEMBL31202790 | 1.00 | PDE5A (1.00) | PDE5APDE3BPDE3APDE1APDE1B | |
| SCHEMBL1190 | 0.95 | PDE5A (0.90) | PDE5APDE3BPDE3APDE1APDE1B | |
| SCHEMBL31202702 | 0.95 | PDE5A (0.90) | PDE5APDE3BPDE3APDE1APDE1B | |
| SCHEMBL5010426 | 0.95 | PDE5A (0.90) | PDE5APDE3BPDE3APDE1APDE1B | |
| SCHEMBL30848678 | 0.94 | PDE5A (0.95) | PDE5APDE3BPDE3APDE1APDE1B | |
| SCHEMBL17342850 | 0.93 | PDE5A (1.00) | PDE5APDE3BPDE3APDE1APDE1B | |
| SCHEMBL29358004 | 0.93 | PDE5A (1.00) | PDE5APDE3BPDE3APDE1APDE1B | |
| SCHEMBL1423 | 0.93 | PDE5A (0.86) | PDE5APDE3BPDE3APDE1APDE1B | |
| Sildenafil SCHEMBL3399278 | 0.92 | PDE5A (0.95) | PDE5APDE3BPDE3APDE1APDE1B | |
| SCHEMBL17390175 | 0.92 | PDE5A (0.85) | PDE5APDE3BPDE3APDE1APDE1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 682 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4687904-A1 | PDE5 INHIBITOR FOR USE IN THE TREATMENT OF MEDICAL CONDITIONS ASSOCIATED WITH MITOCHONDRIAL COMPLEX IV DEFICIENCY | Charité - Universitätsmedizin Berlin (DE) | 2026-02-11 | — | — | EP | claimed |
| US-20250195531-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF PULMONARY HYPERTENSION AND OTHER LUNG DISORDERS | Respira Therapeutics, Inc. (US) | 2025-06-19 | — | — | US | claimed |
| US-12268660-B2 | Oral pharmaceutical formulations of bitter compounds for pulmonary hypertension | AARDVARK THERAPEUTICS INC. (US) | 2025-04-08 | — | — | US | claimed |
| US-20250090534-A1 | Phosphodiesterase-5 Inhibitor Combinations, Methods of Making, and Methods of Use Thereof | VK RESEARCH ASSOCIATES INC. | 2025-03-20 | — | — | US | claimed |
| US-12251582-B2 | Pulmonary hypertension treatment | SONIVIE LTD. (IL) | 2025-03-18 | — | — | US | claimed |
| WO-2025023902-A1 | THE PHARMACEUTICAL COMBINATION COMPRISING PHOSPHODIESTERASE TYPE-5 INHIBITOR, L-ARGININE AND PANAX GINSENG | MONTERO GIDA SANAYI VE TICARET ANONIM SIRKETI (TR) | 2025-01-30 | — | — | WO | claimed |
| WO-2025023901-A1 | THE PHARMACEUTICAL COMBINATION COMPRISING PHOSPHODIESTERASE TYPE-5 INHIBITOR AND L-ARGININE | MONTERO GIDA SANAYI VE TICARET ANONIM SIRKETI (TR) | 2025-01-30 | — | — | WO | claimed |
| US-20240342188-A1 | Use of NEP Inhibitors for the Treatment of Laminitis | CURTAILS LLC (US) | 2024-10-17 | — | — | US | claimed |
| US-20240342187-A1 | USE OF NEP INHIBITORS FOR THE TREATMENT OF GASTROINTESTINAL SPHINCTER DISORDERS | CURTAILS LLC (US) | 2024-10-17 | — | — | US | claimed |
| WO-2024200678-A1 | PDE5 INHIBITOR FOR USE IN THE TREATMENT OF MEDICAL CONDITIONS ASSOCIATED WITH MITOCHONDRIAL COMPLEX IV DEFICIENCY | CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN (DE) | 2024-10-03 | — | — | WO | claimed |
| US-6469012-B1 | POTENT, SELECTIVE INHIBITORS OF CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASES LEAD TO ELEVATED CGMP LEVELS | PFIZER INC | 2002-10-22 | — | — | US | claimed |
| US-20020119974-A1 | Methods and compositions for treating diseases and conditions of the eye | LATIES ALAN M (US) | 2002-08-29 | — | — | US | claimed |
| US-20010053780-A1 | Daily treatment for erectile dysfunction using a PDE5 inhibitor | LILLY ICOS LLC, A DELAWARE CORPORATION | 2001-12-20 | — | — | US | claimed |
| US-6225315-B1 | ADMINISTERING A CGMP PDE INHIBITOR. | PFIZER INC | 2001-05-01 | — | — | US | claimed |
| EP-1074258-A2 | Methods and compositions for treating diseases and conditions of the eye | Pfizer Products Inc. (US) | 2001-02-07 | — | — | EP | claimed |
| EP-1022026-A2 | Pharmaceutical compositions for treating nitrate-induced tolerance | Pfizer Limited (GB) | 2000-07-26 | — | — | EP | claimed |
| EP-0702555-B1 | PYRAZOLOPYRIMIDINONES FOR THE TREATMENT OF IMPOTENCE | PFIZER LTD (GB) | 1998-03-11 | — | — | EP | claimed |
| EP-0463756-B1 | Pyrazolopyrimidinone antianginal agents | PFIZER LTD (GB) | 1995-04-19 | — | — | EP | claimed |
| US-5250534-A | Inhibitors of cyclic guanosine 3*,5*-monophosphate phosphodiesterase | PFIZER INC. (US) | 1993-10-05 | — | — | US | claimed |
| EP-0463756-A1 | Pyrazolopyrimidinone antianginal agents | Pfizer Limited (GB) | 1992-01-02 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12268660-B2 | Oral pharmaceutical formulations of bitter compounds for pulmonary hypertension | PDE5A, TAS2R5, PDE3A | PDE5A 1/4885PDE3B 7/4885PDE3A 3/4885 |
| US-20020119974-A1 | Methods and compositions for treating diseases and conditions of the eye | PDE6C, PDE6D, PDE5A | PDE5A 3/4885PDE3B 8/4885PDE3A 6/4885 |
| US-20010053780-A1 | Daily treatment for erectile dysfunction using a PDE5 inhibitor | PDE5A, PDE3A, PDE2A | PDE5A 1/4885PDE3B 4/4885PDE3A 2/4885 |
| US-20240342188-A1 | Use of NEP Inhibitors for the Treatment of Laminitis | MME, REN, ACE | PDE5A 281/4885PDE3B 465/4885PDE3A 250/4885 |
| US-20240342187-A1 | USE OF NEP INHIBITORS FOR THE TREATMENT OF GASTROINTESTINAL SPHINCTER DISORDERS | MME, REN, ACE | PDE5A 100/4885PDE3B 121/4885PDE3A 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.